Due to the nature of chronic disease, it is common for female patients suffering from chronic diseases to have low levels of the female hormones.

When supplemented, all of the steroid hormones, including the female hormones, have the capacity to interfere with the proper function of various nuclear receptors. This effect is dose-dependent. Marshall Protocol (MP) patients are advised to work with their doctor to use the lowest dose of medication that is effective.

Due to the nature of chronic disease, it is common for patients suffering from chronic diseases to have low levels of hormones. This is often due to high levels of the vitamin D metabolite 1,25-D which interferes with the production of hormones such as T3, testosterone, etc. Because the vitamin D system is dysregulated in chronically ill patients, supplementing with other hormones tends to further dysregulate the receptors rather than increase hormonal expression. Thus, hormone supplementation is contraindicated. If the patient is already on hormone “replacement” therapy, judicious use of low-dose hormone therapy (to relieve intolerable symptoms) may be necessary until the patient is able to wean from the hormones.

Marshall Protocol (MP) patients are advised to work with their doctor to use the lowest dose of medication that is effective.

As patients begin to kill the Th1 pathogens causing their disease, vitamin D metabolism restabilizes and 1,25-D's effects on hormonal stabilization becomes less of an issue. Once this happens, there is no longer a need to take extra hormone supplements, and patients can then wean off their steroids.

I used a bioidentical topical hormone cream for several years which worked great for my menopause symptoms. But when Dr. Marshall's molecular modeling work showed that there could be competition between these hormones and Benicar for the VDR, I decided to wean off the cream. This was no fun at all! But I'm glad I did it.

From a link on the UCSF page::
:
Yaffe, who is associate chair for clinical and translational research in psychiatry and professor of psychiatry, neurology, and epidemiology and biostatistics at UCSF, said she conceived the study in an attempt to resolve contradictory evidence on the neuroprotective effects of estrogen.

“In animal models and molecular studies, it looked as if estrogen had beneficial effects on the brain, especially if administered early,” she said, “while at the same time, research in humans indicated that estrogen therapy was associated with an increased risk of dementia.”

In particular, she said, the Women’s Health Initiative, a nationwide study funded by the National Institutes of Health, showed significant links between estrogen therapy and dementia, as well with as a host of other serious health problems, including breast cancer, stroke, and cardiovascular disease.

“Nonetheless,” said Yaffe, “some scientists have wondered if the problem with estrogen and dementia is that you have to expose women to hormones at a certain critical period, during and just after menopause – and that older age is too late.”

I hope we continue to see summary statements like this in other research:“Yaffe’s conclusion: “We need to go back and think carefully about estrogen. My hope is that this study will help open the door to other studies – that it will tell funding agencies that the question is more complicated than we thought.”
Maybe the medical community can start realizing that it's all more complicated than they have thought….
Marysue